CNBX PHARMACEUTICAL INC - CNBX STOCK NEWS

Cannabics Pharmaceuticals (OTCQB: CNBX) announced positive interim results from its second in-vivo POC study of drug candidate RCC-33, revealing a 30% reduction in tumor volume in colorectal cancer mice after 24 days of oral treatment. This follows prior results showing a 33% reduction via intraperitoneal injection. The study demonstrated statistical significance with a p-value under 0.05. Company executives emphasized progress towards human studies and enhancing drug bioavailability.

Cannabics Pharmaceuticals (OTCQB: CNBX) announced the launch of a research program focused on developing a Breast Cancer antitumor targeting medicine on June 3, 2021. This initiative follows a Melanoma research program initiated in April 2021. The company aims to submit a pre-IND meeting package to the US FDA for its Colorectal Cancer treatment, RCC-33. President Gabriel Yariv stated that preclinical experiments showed promising antitumor results on breast cancer cell lines, while CEO Eyal Barad emphasized the company's unique expertise in developing antitumor formulas.

Cannabics Pharmaceuticals (OTCQB: CNBX) announced the granting of its patent titled "System and Method for High Throughput Screening of Cancer Cells" by the European Patent Office on May 25, 2021. This patent, already granted in Israel and South Africa, is also under examination in the US, Canada, and Mexico. The company emphasizes that this recognition validates its technology and enhances its position in drug discovery, aiding in the development of promising cancer treatment candidates. Cannabics continues to focus on personalized and conventional medicines.

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced the filing of a patent application under the Patent Cooperation Treaty for innovative formulations targeting various cancer types. The application is backed by extensive preclinical data from in-vitro and in-vivo studies. President Gabriel Yariv highlighted the identification of effective formulations that may be developed into drug candidates for cancer treatments. This announcement follows a recent 'Notice of Allowance' from the Mexican Patent and Trademark Office for a different patent application.

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced a 'Notice of Allowance' from the Mexican Patent and Trademark Office for its patent on a high throughput screening method for cancer cells. This follows a similar notice from the European Patent Office in October 2020. CEO Eyal Barad highlighted that the patent is already granted in Israel and South Africa, signifying potential market opportunities in these regions. The company aims to leverage these developments in its drug discovery processes.

Cannabics Pharmaceuticals (OTCQB: CNBX) announced a new research program focused on developing an antitumor medication for melanoma. Following successful preclinical tests showing promising results against melanoma cell lines, the company plans to expand its research and initiate in-vivo studies. The company previously developed Cannabics® RCC-33, which exhibited a 33% reduction in tumor volume and a 35% increase in survival rates in mice. The development aligns with the urgency, as an estimated 200,000 new melanoma cases are expected in the U.S. in 2021.

Cannabics Pharmaceuticals (OTCQB: CNBX) announced a new research program focusing on Psylocibin and Psilocin after receiving a license from the Israeli Ministry of Health. The research will be conducted in the company's laboratories in Rehovot, Israel. CEO Eyal Barad highlighted the company's aim to develop intellectual property for various medical applications and build this initiative into a separate business unit. The development aligns with the growing interest in psychedelic-based medicines, positioning Cannabics favorably in this emerging market.

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced the initiation of an in-vivo Dose Response Study on its proprietary colorectal cancer drug candidate, RCC-33. This study follows promising results indicating a 33% reduction in tumor volume and a 35% increase in survival rates in mice treated with RCC-33. The results from this study will support a product package to be submitted to the FDA alongside a Pre-IND meeting request. The company aims to advance RCC-33 in the clinical and regulatory pathway to enhance treatment options for colorectal cancer patients.

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) released promising results from an in-vivo study on its drug candidate RCC-33, showing a 35% increase in survival rate in mice with human colorectal cancer compared to controls. The experimental group had a mean survival of 31 days versus 23 days in the control group. The company plans to request a pre-IND meeting with the FDA next quarter and aims to initiate Phase 1/2a trials in early 2022. These findings support RCC-33's potential as a treatment option in a market estimated at $10 billion.